newsfilter
← Latest News
Business Wire·

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan

Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701's regulatory, CMC, toxicology, and Phase 1 strategies Appili Therapeutics Inc.